Drug intelligence / Profile preview

PharmAla-1

Development stage: Unknown
Lead developer: PharmAla Biotech
Modality: Small Molecules
Administration: Oral

Overview

**PharmAla-1** is a novel chemical entity (NCE) in the MDXX class of molecules, developed by PharmAla Biotech as the first output of their computational drug development pipeline. It is a patented MDMA analog designed to improve safety properties over the base MDMA molecule for potential use in treating neurological and psychiatric disorders. Preclinical research is ongoing, with proof-of-concept studies initiated, and it has received US Patent Prosecution Highway acceptance and first office action for PCT filing. PharmAla-1 is not classified as a controlled substance worldwide.[7][16][18][22]

Beyond the preview

Go deeper on PharmAla-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmAla-1.

Explore the full profile